$0.36
+0.05 (+17.15%)
Open$0.32
Previous Close$0.31
Day High$0.37
Day Low$0.32
52W High$6.23
52W Low$0.28
Volume—
Avg Volume1.11M
Market Cap5.33M
P/E Ratio—
EPS$-2.76
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+11,154.1% upside
Current
$0.36
$0.36
Target
$40.83
$40.83
$24.77
$40.83 avg
$47.84
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 731.6K | 1.39M | 2.02M |
| Net Income | -50,659,034 | -86,662,479 | 234.8K |
| Profit Margin | -6,925.2% | -6,578.9% | 11.6% |
| EBITDA | -56,050,956 | -101,213,473 | 368.8K |
| Free Cash Flow | — | — | 168.2K |
| Rev Growth | -47.4% | -47.4% | +14.4% |
| Debt/Equity | 0.33 | 0.33 | 0.35 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |